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ABSTRACT
Biosimilars remain a hot topic in rheumatology, and
some physicians are cautious about their application in
the real world. With many products coming to market
and a wealth of guidelines and recommendations
concerning their use, there is a need to understand the
changing landscape and the real clinical and health-
economic potential offered by these agents. Notably,
rheumatologists will be at the forefront of the use of
biosimilar monoclonal antibodies/soluble receptors.
Biosimilars offer cost savings and health gains for our
patients and will play an important role in treating
rheumatic diseases. We hope that these lower costs will
compensate for inequities in access to therapy based on
economic differences across countries. Since approved
biosimilars have already demonstrated highly similar
efﬁcacy, it will be most important to establish
pharmacovigilance databases across countries that are
adequate to monitor long-term safety after marketing
approval.
INTRODUCTION
Biosimilars have been deﬁned extensively else-
where.1–9 In recent years, 20 biosimilar products
have come to market, including the ﬁrst bio-
similar monoclonal antibody (mAb) CT-P13
(biosimilar inﬂiximab), which is available in more
than 70 countries worldwide.10 CT-P13 is
approved in Europe for treatment of rheumatoid
arthritis (RA), ankylosing spondylitis (AS), psori-
atic arthritis (PsA), psoriasis (Ps), Crohn’s disease
(CD) and ulcerative colitis (UC). In November
2015, the European Medicines Agency (EMA)
recommended marketing approval for SB4 (the
ﬁrst biosimilar etanercept in Europe) for treat-
ment of RA, spondyloarthritis (SpA; axial SpA
and non-radiographic axial SpA), PsA and Ps. At
the time of writing, only ﬁlgrastim-sndz has been
approved as a biosimilar in the USA. A Food and
Drug (FDA) Arthritis Advisory Committee
meeting held in February 2016 to discuss CT-P13
recommended approval of CT-P13 for all indica-
tions of the reference product (including extrapo-
lated indications for Ps, PsA and inﬂammatory
bowel disease (IBD)) by a 21 to 3 vote, following
strong positive guidance from the agency’s brief-
ing document (http://www.fda.gov/downloads/
AdvisoryCommittees/CommitteesMeetingMaterials/
Drugs/ArthritisAdvisoryCommittee/UCM484859.
pdf). This further clariﬁes the FDA position on
biosimilar mAbs.
A substantial pipeline of biosimilars is in devel-
opment, with over 700 products reported to be in
preclinical and clinical trials.11 Table 1 presents
molecules under development for use in rheumatic
diseases. Data from randomised controlled trials
(RCTs) with SB2, SB4 and ZRC-3197 have recently
been published,12–14 as have been abstracts on
several biosimilars of adalimumab.
To provide an update on the status of biosimilars
for treatment of rheumatic diseases, a panel of
international experts convened in Frankfurt in
August 2015 for a round-table meeting. The objec-
tives were to address current regulatory positions
and to discuss the requirements for detailed analyt-
ical characterisation and speciﬁc trial designs for
comparing biosimilars with reference products.
A key part of the report comprises health-economic
considerations, need for value-based medicine and
importance of appropriate pharmacovigilance.
There is a widespread and very simple expectation
among patients, treating physicians and healthcare
providers that biosimilars should be highly similar
in efﬁcacy and comparable in safety, including
immunogenicity, but dissimilar (lower) in price in
comparison to their reference products. We also
compare and contrast the approach to the regula-
tory evaluation and approval of biosimilars
between Europe, the USA, Canada and Japan. This
article summarises topics discussed at the meeting
to provide healthcare professionals, patients and
other stakeholders with an overview of recent and
topical changes in the fast-moving world of biosi-
milars extending a previous paper.6
THE BIOSIMILAR REGULATORY ENVIRONMENT
Regulations for biosimilar products are evolving
Regulators have closely followed the small varia-
tions in reference products that develop over time
with process changes.6 Indeed, there is an
International Committee on Harmonisation (ICH)
guidance regarding variability in manufacture of
reference products15 which has subsequently been
applied to biosimilars. Regulatory agencies have
described the analysis of biosimilar trials as a para-
digm shift in drug development,16 occurring at
variable rates in different countries around the
world. To date, 30 applications for biosimilar pro-
ducts have been evaluated in the EU. Of these, 22
biosimilars have been approved in Europe across
six classes, 1 rejected and 7 applications withdrawn
prior to a regulatory decision. Of the 22 biosimilars
approved in Europe across six classes, 2 molecules
were subsequently withdrawn. Six biosimilars,
including erythropoietin and somatotropin, have
also been approved in Japan but, at the time of
writing, only one has been formally approved in
the USA, with one mAb recommended for
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approval.17 Recent congressional testimony by Janet Woodcock,
Director FDA Center for Drugs Evaluation and Research indi-
cated 59 proposed biosimilars for 18 different reference pro-
ducts were enrolled in the agency’s Biosimilar Product
Development Program.18
EMA ﬁrst developed guidelines for approval of biosimilars
using an abbreviated registration process in 2005 and 2006;
these have been updated and revised several times over the
intervening decade, and a speciﬁc guideline for mAbs was
adopted in 2013.1 19–22 Of speciﬁc interest to rheumatologists is
the 2013 European Public Assessment Report (EPAR) for
CT-P13,23 which allowed extrapolation of this biosimilar inﬂixi-
mab to all indications for which the reference product is
approved, despite RCTs conducted only in AS and RA. For
naming of biosimilars, EMA recommends the use of
trademarks.
In the USA, there are now eight FDA guidance documents
addressing biosimilars.2 24–31 A draft guidance on Clinical
Pharmacology Data in 2014 added a requirement for compari-
son between multiple lots of the biosimilar with both US and
ex-US licensed reference products. Draft guidance on
Reference Product Exclusivity (2014) prevents application for
and approval of a biosimilar until 4 years and 12 years fol-
lowing initial approval of the reference product, respectively.
The most recent guidance document on labelling (2015) desig-
nates biosimilars using the proper name with a four-letter
sufﬁx and includes data only for the reference product.30 This
is suggested to facilitate traceability, pharmacovigilance and
collection of real-world data through registries. US FDA has
indicated that guidance regarding interchangeability will not
be issued yet and has asked for commentary as they expect
review of such applications to require a similar amount of
time as would a new Biologics License Application. Thus, sub-
stitution of a biosimilar for the reference product, without
knowledge of the prescribing physician, is not expected soon
in the USA.
In Canada, guidelines for biosimilar approval are laid out in
the 2010 Submission Requirements for Subsequent Entry
Biologics and refer speciﬁcally to EMA guidelines.4 Japanese
biosimilar guidelines were published in 2009 and require that a
biosimilar product be developed on the basis of data that dem-
onstrate its comparability with the reference product in terms of
quality, safety and efﬁcacy, or other relevant data.5 32 33 Other
countries follow WHO guidelines for evaluation of similar bio-
logical products,3 although Brazilian authorities omit informa-
tion about conduct of RCTs from their guidelines.34
Regulatory requirements have evolved, and there is now a
high bar set for both reference and biosimilar products. In
Finland—where biosimilars other than mAbs have been avail-
able since 2008—the position of Finnish Medicines Agency
(Fimea) states that evidence of adverse events related to moving
from a reference product to a biosimilar is yet to emerge and, in
the opinion of Fimea, the theoretical basis for such fears is
weak.35 The risk of adverse effects with use of a biosimilar can
be expected to be similar to those associated with changes in
the manufacturing process of any reference biologic product.36
Many medical societies and other interested organisations have
issued position statements, which indicate that harmonisation
across countries is emerging regarding the development and
acceptance of biosimilars.
Clinical trial design for biosimilar products
As part of the stepwise process to demonstrate biosimilarity and
gain regulatory approval for a biosimilar, EMA, FDA and other
regulatory agencies require a pharmacokinetic/pharmacody-
namic (PK/PD) study in humans and at least one RCT to dem-
onstrate equivalent efﬁcacy and immunogenicity and
comparable safety of the biosimilar and its reference product.
Thus, an equivalence trial design should be employed, con-
ducted in a sensitive population of patients with a disease for
which the reference product is licensed, and immunogenicity
should be compared in this trial. In contrast, the PK/PD study
may be conducted in healthy volunteers as well as in patients.
Use of healthy volunteers for PK/PD studies is becoming more
common, since they provide a more homogenous population in
which variability introduced by diseases is not present.
However, there may be differences in the development of anti-
drug antibodies (ADAbs) between healthy volunteers and
patients, for biosimilars and for reference products. For biosimi-
lars that can be administered either by subcutaneous or intraven-
ous routes, new guidance from FDA states that the PK study
should be performed using a single subcutaneous injection,
since this route is considered to be more likely than intravenous
administration to uncover potential differences in immunogen-
icity between the biosimilar and the reference product.2
The RCT to conﬁrm biosimilarity should be designed with an
equivalence margin based on the difference in the primary end
point between active treatment and placebo derived from a
meta-analysis of prior RCTs of the reference product. The clin-
ical trials of the ﬁrst inﬂiximab biosimilar, CT-P13, evaluated
efﬁcacy and safety at 14 weeks, 30 weeks and 54 weeks.37 38 In
the phase 3 PLANETRA trial, which compared CT-P13 to refer-
ence inﬂiximab in patients with RA, 95% CIs for the difference
between treatments for primary and secondary end points fell
within the prespeciﬁed equivalence margin of ±15%.37
Comparability of CT-P13 with reference inﬂiximab was also
demonstrated in the PLANETAS PK/PD trial in AS, with an
equivalence margin of 80–125% based on 90% CIs.38
Table 1 Biosimilars for rheumatic diseases for which data have
been published in peer-reviewed journals or presented at
international scientific meetings
Reference product Biosimilar molecules
Adalimumab ABP501
BI 695501
CHS-1420
GP-2017
M923
SB5
ZRC-3197
Etanercept CHS-0214
GP2015
HD203
SB4*
Infliximab BOW015†
CT-P13*‡
PF-06438179
SB2
Rituximab CT-P10
GP2013
PF-05280586
*Approved by EMA and multiple other countries.
†Approved in India.
‡Recommended for approval by FDA.
EMA, European Medicines Agency; FDA, Food and Drug Administration.
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Subsequent RCTs conducted for other biosimilars—such as
those that compared the inﬂiximab biosimilar SB2 and etaner-
cept biosimilar SB4 with their respective reference products—
have conﬁrmed highly similar efﬁcacy and comparable
safety.12 13 However, the RCT comparing SB4 with reference
etanercept found this biosimilar to have less and transient
immunogenicity, mainly between week 4–8, and fewer injection
site reactions than the reference product. Consequently, EMA
recently recommended SB4 for marketing approval with full
extrapolation of indications. An issue for clinicians in evaluating
these data is the absence of the SB2 or SB4 phase 1 data from
the published literature, and sponsors are encouraged to share
these results with the regulatory authorities and more fully with
the public in order to support the abbreviated clinical develop-
ment of biosimilars. In general, the authors recommend that
physicians consult individual EPARs and the FDA Purple Book
(online) to obtain more information about the comparability
programmes conducted with biosimilar products.
CHALLENGES REMAINING IN CLINICAL PRACTICE
Switching
With respect to transitioning or switching between a reference
product and a biosimilar, several considerations are relevant for
clinical practice. The absence from many regulatory guidelines
of requirements for multiple switching between reference and
biosimilar products may be seen as a gap in our understanding.
Of note, we often do not see studies in the public domain that
address manufacturing changes of a reference product, even
though post-translational differences occurred. It is left to the
regulators to require such studies, which remain conﬁdential
between sponsors and FDA, although EMA does issue a notiﬁ-
cation. Drift may occur at any time, but there is no need for
additional trials as long as batches remain within the predeﬁned
speciﬁcations for the product.
Most RCTs investigating transitioning to a biosimilar have
incorporated only one randomised switch from the reference
product to the biosimilar that occurs after assessment of the
primary end point. Currently several efforts are underway to
collect real-world data about transitioning.10 One example is
the NOR-SWITCH study, supported ﬁnancially by the
Norwegian government. NOR-SWITCH was designed as a non-
inferiority study over 12 months to evaluate maintenance of efﬁ-
cacy as well as adverse event monitoring following transitioning
from reference to biosimilar inﬂiximab, compared with main-
taining treatment with the reference product in patients with
RA, SpA, PsA, Ps and IBD. Eligible patients on stable treatment
for at least 6 months were randomised to either continue
treatment with reference inﬂiximab or to transition to CT-P13.
The primary end point of this study is disease worsening.
Enrolment was completed in June 2015; 498 patients were ran-
domised. Those who complete 12 months’ treatment are then
asked to participate in an open-label follow-up study during
which all patients will receive the biosimilar for 26 weeks.
Results from this study are expected to be available at the end
of 2016.39
Early transition data from the PLANETAS extension study
showed comparable rates of serious treatment emergent adverse
events (TEAEs) between maintenance and transition groups
(4.4% vs 4.8%), but fewer patients experienced more than one
TEAE during the 2nd year with continuation of CT-P13 com-
pared with those transitioning to CT-P13 (48.9% vs 71.4%)—
predominantly due to more mild/moderate events.40 These data
were published in abstract form in sufﬁcient detail to allow
analysis of comparability for safety, as illustrated by statistical
considerations (table 2). On the other hand, in the
long-term extension of the Japanese study of CT-P13, 41 of 43
ADAb-negative patients remained negative and 10 ADAb-
positive patients became negative after transitioning from refer-
ence product to CT-P13 or having the CT-P13 dose escalated (Y
Tanaka, et al. Evaluation of safety and efﬁcacy of CT-P13 in
patients with rheumatoid arthritis when CT-P13 is continued
throughout the extension study and switched from the reference
drug innovator inﬂiximab. manuscript submitted). ADAb posi-
tivity and hypersensitivity reactions during the 2nd year of both
PLANETRA and PLANETAS did not differ signiﬁcantly
between patients exposed to both reference and biosimilar as
compared with those who received only the biosimilar over
2 years. Recent studies have demonstrated that the binding spe-
ciﬁcity of ADAb to reference inﬂiximab and CT-P13 is identical:
the same epitopes are recognised on both mAbs.43 44
Although close analytical similarity of the critical attributes of
a biosimilar with its reference product suggests that clinical dif-
ferences will be unlikely, RCTs for biosimilars, which typically
enrol fewer than 600 participants, are underpowered to identify
unexpected rare adverse events.45 Thus, careful postmarketing
pharmacovigilance is important for both biosimilars and refer-
ence products.
With respect to the naming of biosimilars, many have debated
the need for these agents to be named differently from their ref-
erence products to inform, document switches and facilitate
pharmacovigilance.46 WHO has suggested that each inter-
national non-propriety drug name be followed by a four-letter
sufﬁx to identify each brand3 47 48 recently endorsed by FDA in
their 2015 draft guidance.30 To date, EMA has required brand
Table 2 Limitations of safety data derived from trials: statistical reminders when interpreting regulatory trials for reference and biosimilar
products
Test Uses and interpretation Example
Bonferroni
correction41
When you perform a hypothesis test in statistics, a p value helps you determine the significance
of your results. The more often you repeat a test in a study, the more likely it is to show a
positive result by chance (a false positive). The simplest way to compensate for this is to limit
comparisons to only the most clinically relevant and critical outcome. If multiple comparisons
are needed, the measure of statistical confidence (traditionally taken to be p≤0.05) needs to be
adjusted downwards. The Bonferroni correction is the simplest method for this.
Number of tests Bonferroni’s
adjusted p value
2 0.025
3 0.0167
4 0.0125
10 0.005
The ‘rule of 3’42 In statistical analysis, the ‘rule of 3’ states that if a certain event did not occur in a sample with
n subjects, then you can approximate that the upper limit of 95% CI=maximum risk=3/n.
When n is greater than 30, this is a good approximation to results from more sensitive tests.
For example, if a drug was studied in 900 patients, you
could be 95% certain that any unreported toxicity should
occur at a rate of <1 in 300 (<3/900). To exclude less
frequent events requires larger trial sizes and emphasises
the importance of pharmacovigilance reporting.
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naming which in practice has worked well: a survey of 13 790
biologic entries in the EUdravigilance system showed >96%
ability to track the biosimilar.49 In the future it is expected that
biosimilars and reference products will be substituted back and
forth repeatedly as will biosimilars of the same reference
product.2 10 28 There will be a need to introduce new ways to
track and document which products a patient receives—for
example patient passports or similar traceability methods. Such
strategies for drug monitoring and immunogenicity assessments
before and after switching will facilitate mandated as well as vol-
untary pharmacovigilance. Accumulated experience with biosi-
milars of smaller therapeutic proteins than mAbs have not
indicated a safety risk of switching between reference products
or biosimilars.50
Extrapolation of indications
Extrapolation across clinical indications has a basis in pre-
existing scientiﬁc and regulatory principles and practice.51 At
present EMA and US labels for a biosimilar are the same as for
the reference product and do not include information about the
biosimilar itself. The only way for prescribers to obtain such
information is through publications or regulatory agency docu-
ments such as EPARs and FDA Purple Book. In the case of
tumour necrosis factor inhibitors (TNFis) with multiple clinical
indications, no biosimilar is likely to be studied across all rele-
vant diseases, provided they share the same mechanism of
action. While no head-to-head trials between different TNFis
exist, it is clear that all mAb-based TNFis, despite differences in
their molecular characteristics, have efﬁcacy across the same
indications; therefore a molecularly correctly developed biosimi-
lar mAb is expected to also have that quality. Although preclin-
ical analytical structural and functional data and toxicology with
the currently approved CT-P13 indicated biosimilarity in all
respects, this was ultimately conﬁrmed only in RCTs conducted
in AS and RA, but not PsA, Ps or IBD. In Japan, CT-P13 was
tested in RA but approval also included Ps, PsA and IBD.52
Furthermore, dose increases from 3 mg/kg to 10 mg/kg and
treatment intervals varying from every 4–8 weeks were
allowed.53 54 Conversely, in Canada the theoretical
pathophysiological mechanism of disease was identiﬁed as a
point to consider in support of indication extrapolation; and
CT-P13 was approved in PsA and Ps but not in CD or UC,
although this is again under review.55–57 In the USA, the FDA
Arthritis Advisory Committee recently recommended approval
of CT-P13 across all clinical indications approved for inﬂiximab.
Regulatory agencies have in general offered similar conclusions
regarding extrapolation, with the exception of Canada (table
3)1 4 5 28 59 but there exists variability between society
positions.60
Disease type, genetics, administered dose and background
therapy can affect immunogenicity. Similar to other TNFis, it
has been observed that ADAbs were more frequent in patients
with RA than patients with AS with both inﬂiximab reference
product and biosimilar, despite use of methotraxate (MTX)
in RA.37 38 61 This suggests that RA is an important trial indica-
tion to obtain insights into immunogenicity.
Many of the concerns raised with regard to extrapolation
appear to be hypothetical,10 and will likely not be problematic
in the long term. All biosimilars will require postmarketing sur-
veillance to track ongoing safety and immunogenicity. In the
EU, postmarketing surveillance is a task performed by the indi-
vidual member states; therefore, national programmes and
required safety data may vary—we have yet to better understand
requirements mandated in Canada and the USA. Overall, com-
patibility and consistency of these databases should be a major
objective, so that safety signals can be detected in a timely
fashion. To ensure proper assessment of all aspects, it may be
wise to also include batch numbers of all biologics in registries,
so that the variability among biosimilars and reference products
can be compared.
BIOSIMILARS AND ACCESS TO HEALTHCARE
Experience in oncology
Oncologists in the EU have had access to biosimilar products for
over 8 years. These have transformed care by increasing access
to treatment.62 At the outset, many learned societies suggested
cautious use of biosimilars (especially in extrapolated or paediat-
ric populations). Based on evidence this cautious approach was
Table 3 Regulatory guidance on extrapolation
Agency Requirements for extrapolation Issues precluding extrapolation
Europe1 ▸ In certain cases, it may be possible to extrapolate therapeutic similarity shown in
one indication to other indications of the reference medicinal product.
▸ Case-by-case decision based on the ‘totality of evidence’.
▸ Possible safety issues in different subpopulations should also be addressed.
Justification will depend on, for example, clinical experience, available
literature data, whether or not the same mechanisms of action or the
same receptor(s) are involved in all indications.
Canada4 58 ▸ Indication of a biosimilar must be the same as its reference product.
▸ Similarity must be demonstrated by comprehensive comparative characterisation.
▸ Type and design of trials using sensitive populations and end points must be
capable of detecting changes in the end points chosen.
▸ Consider route of administration; posology and PK/PD profiles in each indication
considered.
▸ Minor differences in active ingredients or mechanism of action.
▸ Differences in pathophysiology of the disease/s.
▸ Differences in clinical experience compared with reference drug.
Australia59 ▸ In certain cases, it may be possible to extrapolate therapeutic similarity shown in
one indication to other indications of the reference medicinal product.
▸ Possible safety issues in different subpopulations should also be addressed.
Justification will depend on, for example, clinical experience, available
literature data, whether or not the same mechanisms of action or the
same receptor(s) are involved in all indications.
Japan5 33 Extrapolation to the Japanese population should be justified according to the ICH
guidelines.
Japanese guideline describes that it may be possible to extrapolate
from one indication to other indications of the reference product if the
mechanism of action is the same.
USA28 ▸ Use a study population and treatment regimen adequately sensitive.
▸ Sufficient scientific justification for each condition.
▸ Only for conditions of use previously licensed for the reference product.
▸ Demonstration requires detailed information regarding similar mechanism of action
between biosimilar and reference product.
Extrapolation based on totality of the evidence.
PK/PD, pharmacokinetic/pharmacodynamic.
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not necessary—the ﬁrst wave of biosimilar agents have exceeded
5 years’ use although they were peptides, not mAbs.29 49 63 64
In light of the evidence collected, strong endorsement of use of
biosimilars by groups such as the European Organisation for
Research and Treatment of Cancer occurred even in 2010.65
Conﬁrmation that regulatory measures to control both manufac-
turing changes of reference products and biosimilars are effect-
ive are evident from the experience of the ﬁrst three classes of
biosimilars approved by EMA that do not indicate additional
safety risks from switching between reference products and bio-
similars. Furthermore, a recent meta-analysis of switching
between human recombinant growth factors and granulocyte
colony stimulating agents showed no different safety signals in
>12 000 patients in 58 clinical trials, as well as across all the
individual European pharmacovigilance data.66
Biologic therapies are important in oncology, but they are also
pinpointed as the reason for escalating global healthcare costs.67
Oncology cannot afford the current trajectory of drug
pricing.68 69 The next generation of biosimilars (trastuzumab,
rituximab, cetuximab) will be vital in managing budgets and
coping with increasing cancer incidence—putting great pressure
on physicians to justify any decision not to switch patients.70 71
This experience in oncology is valuable to rheumatologists in
considering the introduction of biosimilars into clinical practice.
Health-economic considerations in rheumatology
The expense of biologic agents is a major issue. What should a
biologic disease-modifying antirheumatic drug (bDMARD)
really cost? How much shareholder value above and beyond the
return of investment should society pay? What should subse-
quently marketed biosimilars cost given that the ﬁrst has already
led to a price reduction?
The QUEST-RA study found huge disparities in disease activ-
ity in patients with RA across 25 countries, with average disease
activity score in 28 joints (DAS-28) scores ranging from 3.1
(The Netherlands) to 6.0 (Kosovo). Interestingly, there was a
strong inverse association between gross domestic product
(GDP) and DAS-28, indicating that disease burden is strongly
related to country welfare.72 More recently, data from the
COMORA study revealed that the association between disease
activity and socioeconomic status is evident both at an individ-
ual level (measured as education) and a country level (measured
as GDP).73
Two other groups performed surveys to compare accessibility
and criteria regulating reimbursement of bDMARDs, and
demonstrated large price differences between countries.
Accessibility based on availability, affordability and acceptability
varied across countries, again strongly related to GDP—criteria
for regulating treatment were stricter in less afﬂuent coun-
tries.74 75 Real-world utilisation of bDMARDs was assessed in
six central and eastern European countries. The number of
patients with RA receiving bDMARDs varied signiﬁcantly:
Poland 1.3%, Bulgaria 2.6%, Romania 4.1%, the Czech
Republic 4.2%, Hungary 8.4% and Slovakia 10.0%.76 These
data indicate large inequities in health status, access to
bDMARDs and use of regulatory criteria—the relationship
between these dimensions and GDP should support the import-
ance of availability of cheaper therapies such as biosimilars pro-
vided there is willingness to replace reference products.
Budget impact savings
The role of biosimilars in reducing costs and increasing patient
access to bDMARDs in rheumatology has been analysed
recently.77 The budget impact of switching patients to CT-P13
for RA in the UK, Italy, France and Germany is estimated over
5 years to offer savings of €233 million and €433.5 million for
20% and 30% discount scenarios, respectively.78 With a 30%
discount, an additional 7561 patients could be treated across
these four countries and the Netherlands using drug cost
savings after 1 year of biosimilar inﬂiximab.79 These data are
supported by another analysis in Italy, which demonstrated that
availability of CT-P13 could lead to cumulative national cost
savings of €47 million over 5 years.80 In Ireland the total
savings over 5 years with use of CT-P13 in RA has been esti-
mated to be €5.3 million.81 The budget impact of CT-P13 intro-
duction has also been estimated for patients with RA in
Bulgaria, the Czech Republic, Hungary, Poland, Romania and
Slovakia. Over 3 years, and assuming a 25% discount, savings of
€15.3 million could be made in the ﬁrst scenario, and €20.8
million in the second, allowing treatment of an additional 1200
or 1800 patients across the six countries, respectively.82
In practice, savings are already evident. In Japan CT-P13 has
been launched as Inﬂiximab-BS-NK, its price is reduced by 67%
compared with reference inﬂiximab83 and in Norway by 69%.84
Recent data from South Korea 15 months after introduction of
CT-P13 show that a ﬁfth of all inﬂiximab claims were for the
biosimilar. More interesting is the indication that the use of
TNFi increased overall85—suggesting that additional patients
are being treated.
In the UK, the National Institute for Health and Care
Excellence (NICE) has given guidance to rheumatologists that
‘treatment should be initiated with the least expensive drug’86
while in Belgium and Germany there is a quota system, which
drives physicians to prescribe biosimilars in up to 40% of their
patients.87 Thus, cost remains an important consideration
regarding access to treatment and will drive the implementation
of biosimilars.
Country example: Norway
Norway has a tender system where each company offers a price
for their product for a time period of 12 months. The least
expensive alternative will be recommended, since no study has
demonstrated a signiﬁcant difference in efﬁcacy and safety on a
group level among the various TNFis across SpA, PsA, Ps or
IBD. This competitive system has helped to reduce prices of
bDMARDs in Norway. Biosimilar inﬂiximab was approved in
Norway in 2013, priced 33–39% lower than the reference
product from 2014. For 2015 prices were further reduced—
51–69% lower than the reference product—making biosimilar
inﬂiximab the preferred bDMARD for all six indications when
initiating a bDMARD or switching to a TNFi in naïve
patients.84 The cost for the biosimilar inﬂiximab for the 1st year
of treatment in RA is about 20% the cost of adalimumab.84
Motivated by cost saving many departments in Norway have
initiated switching of patients from reference to biosimilar
inﬂiximab even before results from the NOR-SWITCH are
available. As of September 2015 the total number of depart-
ments using inﬂiximab had increased approximately 50% since
2014; 80% with biosimilar inﬂiximab. Recent data from
Denmark similarly show that biosimilar inﬂiximab has about
90% of the market since switching was mandated by payers to
reduce costs.88
The results of the Norwegian tender for 2016 gave some
changes—biosimilar inﬂiximab is still the cheapest alternative
with a price about 60% lower than Remicade. SB4 (Benepali)
was offered at a price which is 47% lower than the regular price
of reference etanercept (but is more expensive than certolizu-
mab; personal communication Tore K Kvien).
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Better access and health gain
It has been argued that a simple cost saving is not sufﬁcient to
justify biosimilar switching—there also needs to be an overall
health gain. Clinicians are said to be more willing to use biosi-
milars if their patients are beneﬁciaries of the cost savings.89
Alternatively, if a biosimilar has no clinically meaningful differ-
ence in efﬁcacy or safety with the reference product, then cost
saving should be sufﬁcient moral reason to promote its use in a
world where medical resources are ﬁnite. The availability of bio-
similars will allow patients to receive medications that might
otherwise be unaffordable to them.
Physicians therefore need to be aware of costs to their patients
and wider societal implications of delaying biosimilar use
without very good reason. Assuming a conservative 30% price
discount for biosimilar inﬂiximab, this would represent cost
savings in Europe of more than €530 million every year. If the
50% price reductions seen in the Nordic nations are achieved
across the EU, the potential savings to reinvest in better health-
care could exceed €880 million annually.88
Physicians are reminded by WHO of their responsibility to
the community when prescribing medicines with the lowest cost
to patients and their communities.90 Costs should also be taken
into consideration when developing treatment recommenda-
tions.91 In 2014, three of the four top-selling global therapies
were bDMARDs—all TNFis. If even one of these agents
becomes signiﬁcantly cheaper, the changing pattern of use
becomes a serious consideration for affordable care. The 2013
update of the European League Against Rheumatism recommen-
dations for use of DMARDs and bDMARDs highlight in their
overarching principles that medicinal costs should be considered
when prescribing these therapies.92 Similarly, the 2015
American College of Rheumatology guidelines raise cost as an
important issue.93
DISCUSSION
Biosimilars have entered clinical practice, and they are already
changing access to therapies in rheumatology.94 Although mAbs
may be more complex than some biologics used in oncology,
there are many parallels. Biosimilars offer the potential to
reduce acquisition costs of bDMARDs, removing current
inequity in their use between countries with high and low
GDPs.74 Harmonisation of regulatory guidance and recommen-
dations on the use of biosimilars may help guide physicians’
decisions. Rheumatologists will be at the forefront of the use of
biosimilar mAbs, in terms of recommendations for use but also
design and analyses of RCTs. In the UK, NICE concluded that
there was no compelling evidence to distinguish between TNFis
on the basis of clinical effectiveness when making recommenda-
tions—prompting a broader appraisal of the use of all
bDMARDs.86
For patients, biosimilars will increase affordability of treat-
ment options and improve accessibility. Understandably,
evidence-based information is needed to inform choices.95
Patients should be kept informed about which products they are
receiving, and should not be transitioned without their knowl-
edge. Reduced costs are important but heterogeneous healthcare
systems may lead to substantial price differences between coun-
tries which will require attention as resources for improved care
of our patients become limited.
Pharmacovigilance remains the key to incorporating biosimi-
lars into clinical practice and requires collection of safety data
across nations to detect even small safety signals. Sponsors are
required to submit a risk-management plan (RMP) to EMA
when applying for marketing authorisation, and to FDA at the
time of ﬁnal approval. RMPs in general lay out information on
a product’s safety proﬁle, including how risks will be prevented
or minimised and plans for further studies to gain additional
knowledge.96 They are resubmitted during periodic safety
update reports. An example can be found in the EPAR for
Remsima/Inﬂectra.23 97 Similarly, the RMP for the inﬂiximab
reference product speciﬁed data collection across several regis-
tries, including ARTIS, BIOBADASER, BSRBR, RABBIT,
BADBIR, ENCORE, OPUS, the paediatric IBD registry,
PSOLAR and likely CORRONA. With biosimilars also come
new insights into the immunogenicity of bDMARDs, with
potentially broader use of ADAb testing in clinical practice.
It remains an academic responsibility to guide implementation
of biosimilars into clinical practice while simultaneously con-
tinuing to search for improved therapeutic approaches and treat-
ment sequences. More than 40 biosimilar candidates are in
development for use in rheumatic diseases, and this group will
continue to carefully monitor data relating to their efﬁcacy and
safety. It will be important to share information with clinicians
and patients as more biosimilars are introduced (box 1).
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Box 1 Group recommendations for the future
▸ Pay close attention to which biosimilar product is being
prescribed and used.
▸ Prescribe using the proper name or trade name with sufﬁx.
▸ Contribute to local and international pharmacovigilance
efforts (registries).
▸ Conduct quality pharmacovigilance to monitor long-term
safety, with harmonisation of data collection across
registries.
▸ Encourage transparency in drug characterisation.
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